Senseonics Q4 revenue $8.3M, net loss $15.5M; guides FY25 revenue $34-38M

Senseonics Holdings, Inc.

Q4 revenue $8.3M (up from $8.0M YoY); net loss $15.5M ($0.02 loss per share).
Full-year 2024 revenue $22.5M (flat YoY); net loss $78.6M ($0.12 loss per share).
Patient base grew 56% in 2024 to ~6,000 global patients; Eversense 365 FDA approved and launched.
FY2025 guidance: revenue $34-38M, gross margins 25-30%, cash usage $50-60M.
Post-quarter: raised ~$27M via ATM, repaid $20.4M convertible notes; debt reduced to $35M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.